OOIR: Observatory of International Research

Papers

(The H4-Index of Inflammatory Bowel Diseases is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
ARTHRITIS AND ARTHRALGIA AS EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB: A META-ANALYSIS	232
Correction to: Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease	87
LOWER MORTALITY RISK WITH COMBINATION THERAPY WITH ANTI-TNF THERAPY AND THRIOPURINE COMPARED TO THIOPURINE ALONE IN ELDERLY PATIENTS WITH UC	82
DEPRESSION MAY BE A STRONGER UNIQUE PREDICTOR OF FATIGUE THAN SELF-REPORTED IBD DISEASE ACTIVITY	77
EPITHELIAL MITOCHONDRIAL DYSFUNCTION IN CHRONIC POUCHITIS	75
GROUP 3 INNATE LYMPHOID CELLS RELY ON ER STRESS RESPONSE FOR CYTOKINE PRODUCTION IN IBD	68
COMPARATIVE EFFICACY OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UC PATIENTS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS	66
COMPARATIVE EFFECTIVENESS OF ORAL JANUS KINASE INHIBITORS VERSUS VEDOLIZUMAB IN ULCERATIVE COLITIS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS	56
DELAYS IN THE ADMINISTRATION OF BIOLOGIC THERAPIES AND ADVERSE OUTCOMES IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY	55
Improving Brain–Gut Studies in Crohn’s Disease: Methodological Considerations	52
Gut Feelings Matter: The Unresolved Questions of Irritable Bowel Syndrome-Like Symptoms in Inflammatory Bowel Disease in Remission	52
IDENTIFYING THE ROLE OF ACINETOBACTER CALCOACETICUS IN DRIVING INTESTINAL INFLAMMATION	51
Inflammatory Bowel Disease and Risk of Global Cardiovascular Diseases and Type 2 Diabetes	49
COMPARATIVE RISK OF LYMPHOMA IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH THIOPURINES AND/OR ANTI-TNF AGENTS: AN UMBRELLA REVIEW OF META-ANALYSES	48
Phosphoproteomics Reveals Novel Insights into the Pathogenesis and Identifies New Therapeutic Kinase Targets of Ulcerative Colitis	48
AN INTEGRATED MULTI-OMIC APPROACH REVEALS A SHARED SIGNATURE OF IMMUNE ACTIVATION AND METABOLIC COLLAPSE IN ULCERATIVE COLITIS AND RHEUMATOID ARTHRITIS	46
Author’s Response to Comment on “Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease”	45
Following Through: The Impact of Culinary Medicine on Mediterranean Diet Uptake in Inflammatory Bowel Disease	45
COMPARATIVE PERIOPERATIVE OUTCOMES OF LUMBAR SPINAL SURGERY IN PATIENTS WITH AND WITHOUT INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS	45
Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study	45
INFLAMMATORY BOWEL DISEASE IN YOUTH UNDER 20 FROM 1990-2019: A GLOBAL PERSPECTIVE ON REGIONAL AND NATIONAL VARIATIONS FROM THE GBD 2019 ANALYSIS	44
ROLE OF EPITHELIAL LTA4H-LTB4 SIGNALING IN RESOLUTION OF COLONIC MUCOSAL WOUNDS	43
DEVELOPMENT OF A NEXT GENERATION ENGINEERED LIVE MICROBIOME BIOTHERAPEUTIC, E COLI NISSLE 1917-TTR, FOR ULCERATIVE COLITIS	43
TERTIARY LYMPHOID STRUCTURES (TLS) EXPANSION PARALLELS ILEITIS PROGRESSION IN TNFΔARE MICE, REQUIRES β7 INTEGRIN AND CCR7, AND DECREASES IN SIZE AFTER GLUCOCORTICOID ADMINISTRATION	42
EPIGENETIC REPRESSORS MAINTAIN TREG STABILITY IN A FOXP3-INDEPENDENT MANNER	42

EVALUATING POUCH RELATED OUTCOMES WITH GLUCAGON LIKE PEPTIDE-1 RECEPTOR ANTAGONISTS IN PATIENTS WITH ILEAL POUCH ANAL ANASTOMOSIS—A DATABASE STUDY IN THE UNITED STATES	41
Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN	41
OCTN1 variants shape innate immunity and predict individual response to anti-TNFα in ulcerative colitis patients: An exploratory study	39
The Prevalence of Chronic Opioid Use in Patients With Inflammatory Bowel Disease: A Nationwide Danish Register-Based Study Over a 25-Year Period of Time	39
GRANZYME A-PRODUCING CD4 T CELLS ARE DRIVERS OF IMMUNE CHECKPOINT BLOCKADE-INDUCED COLITIS	39
Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease	39
Impact of Psychosocial and Neurodevelopmental Disorders on Pediatric Ulcerative Colitis: A Single-Center, Retrospective, Observational Study	38
THE ONSET AND SEVERITY OF ULCERATIVE COLITIS IN IL-10 -/- MICE IS NOT DEPENDENT ON FECAL MICROBIOTA TRANSPLANTATION FROM ULCERATIVE COLITIS PATIENTS	36
Clinical significance of isolated periappendiceal red patch in ulcerative colitis: A systematic review, meta-analysis, and meta-regression	35
Trained immunity: Breaking a dogma and a missing opportunity in IBD?	34
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OL	34
Racial and Ethnic Disparities in Patients With Inflammatory Bowel Disease: An Online Survey	34
Pharmacogenomic Assessment of Genes Implicated in Thiopurine Metabolism and Toxicity in a UK Cohort of Pediatric Patients With Inflammatory Bowel Disease	34
Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis	34
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED	34